Symbicort Turbuhaler信必可

Symbicort Turbuhaler

budesonide + formoterol

Manufacturer:

AstraZeneca

Distributor:

Zuellig
/
Four Star
Concise Prescribing Info
Contents
Per 80/4.5 mcg turbuhaler Budesonide 80 mcg, formoterol 4.5 mcg. Per 160/4.5 mcg turbuhaler Budesonide 160 mcg, formoterol 4.5 mcg. Per 320/9 mcg turbuhaler Budesonide 320 mcg, formoterol 9 mcg
Indications/Uses
Regular treatment of asthma where combination therapy w/ inhaled corticosteroid & long-acting β-agonist is appropriate. 160/4.5 mcg & 320/9 mcg turbuhaler Symptomatic treatment of COPD.
Dosage/Direction for Use
Asthma, maintenance therapy 80/4.5 mcg & 160/4.5 mcg turbuhaler Adult ≥18 yr 1-2 inhalations bd. Max: 4 inhalations bd. Adolescent 12-17 yr 1-2 inhalations bd. 80/4.5 mcg turbuhaler Childn ≥6 yr 2 inhalations bd. 320/9 mcg turbuhaler Adult ≥18 yr 1 inhalation bd. Max: 2 inhalations bd. Adolescent 12-17 yr 1 inhalation bd. Asthma, maintenance & reliever therapy 80/4.5 mcg & 160/4.5 mcg turbuhaler Adult & adolescent ≥12 yr 1 inhalation bd or 2 inhalations in either morning or evening. Take 1 additional inhalation as needed. Max: 6 inhalations on a single occasion; 8 inhalations/day. 12 inhalations/day could be used for a limited period. COPD Adult 160/4.5 mcg turbuhaler 2 inhalations bd. 320/9 mcg turbuhaler 1 inhalation bd.
Contraindications
Hypersensitivity to budesonide, formoterol, or lactose.
Special Precautions
Use for the shortest time required to achieve control of asthma symptoms. Long-term use may be considered only in patients whose asthma cannot be adequately controlled on asthma controller medications. Taper dose when discontinuing treatment. Thyrotoxicosis; phaeochromocytoma; DM; untreated hypokalaemia; hypertrophic obstructive cardiomyopathy; idiopathic subvalvular aortic stenosis; severe HTN; aneurysm or other severe CV disorders; quiescent pulmonary TB; fungal & viral airway infections. Take maintenance dose as prescribed even when asymptomatic. Not for regular prophylactic use eg, before exercise. Rinse mouth w/ water after inhalations in case of oropharyngeal thrush. Pregnancy & lactation.
Adverse Reactions
Palpitations, oropharyngeal candidiasis, pneumonia in COPD patients, headache, tremor, mild throat irritation, cough, hoarseness.
Drug Interactions
Increased plasma levels w/ potent CYP3A4 inhibitors (eg, ketoconazole, itraconazole, voriconazole, posaconazole, clarithromycin, telithromycin, nefazodone & HIV PIs). Weakened or inhibited effect w/ β-blockers. Prolonged QTc-interval & increased risk of ventricular arrhythmias w/ quinidine, disopyramide, procainamide, phenothiazines, terfenadine, TCAs. Impaired cardiac tolerance towards β2 sympathomimetics w/ levodopa, L-thyroxine, oxytocin, alcohol. Risk of hypertensive reactions w/ MAOIs, furazolidone & procarbazine. Elevated risk of arrhythmias w/ anaesth. Potential additive effect w/ other β-adrenergic drugs or anticholinergic drugs. Increased disposition to arrhythmias due to hypokalaemia w/ digitalis glycosides. Risk of hypokalaemia w/ xanthine derivatives, corticosteroids & diuretics.
ATC Classification
R03AK - Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics ; Used in the treatment of obstructive airway diseases.
Presentation/Packing
Form
Symbicort Turbuhaler 160/4.5 mcg turbuhaler
Packing/Price
60 dose x 1's
Form
Symbicort Turbuhaler 80/4.5 mcg turbuhaler
Packing/Price
60 dose x 1's
Form
Symbicort Turbuhaler 320/9 mcg turbuhaler
Packing/Price
60 dose x 1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in